Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
-
Subject Areas on Research
-
Brief Report: Antibody Responses to Quadrivalent HPV Vaccination in HIV-Infected Young Women as Measured by Total IgG and Competitive Luminex Immunoassay.
-
Delayed dosing intervals for quadrivalent human papillomavirus vaccine do not reduce antibody avidity.
-
Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection.
-
Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial.
-
Increasing HPV vaccination series completion rates via text message reminders.
-
Paediatricians' attitudes and practices towards HPV vaccination.
-
Pain in adolescent girls receiving human papillomavirus vaccine with concomitantly administered vaccines.
-
Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions.
-
Reductions in human papillomavirus-disease resource use and costs with quadrivalent human papillomavirus (types 6, 11, 16, and 18) recombinant vaccination: the FUTURE Study Economic Evaluation.
-
Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial.